Ann Weaver Hart, President of the University of Arizona outlines the basics of the GME Crisis and offers a solution
Category Archives: Blogs
AZBio Blogs
Gore Receives First FDA Approval for Endovascular Repair of Aortic Dissection
Conformable GORE® TAG® Thoracic Endoprosthesis First to Receive Indication for Aneurysm, Trauma and DissectionContinue reading
TGen’s ‘Medical Miracle’ — now wheelchair-free — celebrates 13th birthday
Shelby Valint, following TGen genomic sequencing, able to walk and talk, even run and dance; urges public to help other children like herContinue reading
Knowledge In Numbers: Pairing Digital Pathology with Integrated Biostatistics
Rapid changes in the pharmaceutical industry and in the discipline of pathology expand the need for biostatisticsContinue reading
Without fair payment, biomedical innovation cannot make it the last mile.
Biomedical innovations in the area of molecular diagnostics are the framework for a new golden age of medicine. Unfortunately, a hurdle on the path from discovery to development to delivery could block these life sustaining and life saving innovations from getting to the patient.Continue reading
State of Biomedical Innovation – Global Leaders share ideas at Brookings
On July 16, the Engelberg Center for Health Care Reform at Brookings hosted the second annual State of Biomedical Innovation conference.Continue reading
BioPharm Insight Analysis: Ulthera
Ulthera evaluating exit strategies in wake of turning cash-flow positive – CEO BioPharm InsightContinue reading
Iron Horse Diagnostics partnership for ALS diagnostics on the horizon
Iron Horse Diagnostics partnership for ALS diagnostics on the horizon, raising USD 4m for TBI program
- Two 250-patient TBI trials planned for when funding is in place
- ALS diagnostics validation process to be complete in four months
- Seeking CRO for ALS, and eventually TBI, diagnostics trialsContinue reading
MSDx Welcomes David McCaleb to its Board of Directors
MSDx, Inc., announced today that David McCaleb has joined its Board of Directors. With over thirty years of experience in leading pharmaceutical companies and biotech start-ups, his successful track record in commercialization and fundraising will augment the MSDx team. Continue reading